ENDRA Life Sciences (NDRA) Non-Current Assets (2016 - 2026)

ENDRA Life Sciences has disclosed Non-Current Assets across 11 years of filings, most recently posting $2.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 192.97% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $7.7 million (down 16.36% YoY), while the FY2025 annual figure was $2.9 million, up 183.29% from the prior year.
• Non-Current Assets grew to $2.9 million in Q1 2026, from $2.9 million in the prior quarter.
• Over the last five years, Non-Current Assets for NDRA reached as high as $3.9 million in Q4 2022 and fell as low as $778054.0 in Q3 2022.
• The 5-year median for Non-Current Assets is $1.2 million (2023), against an average of $2.0 million.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 398.99% — and 2025, when it plunged 74.4%.
• A 5-year view of Non-Current Assets shows it stood at $3.9 million in 2022, then decreased by 4.45% to $3.7 million in 2023, then sank by 72.63% to $1.0 million in 2024, then surged by 183.29% to $2.9 million in 2025, then gained by 0.54% to $2.9 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $2.9 million, $2.9 million, and $915399.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.